Genenta Science (GNTA) Expected to Announce Quarterly Earnings on Wednesday

Genenta Science (NASDAQ:GNTA) is expected to post its resultson Wednesday, September 2nd. Analysts expect the company to announce earnings of ($0.2741) per share for the quarter.

Genenta Science Stock Up 2.0%

GNTA opened at $1.02 on Tuesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 14.16 and a quick ratio of 14.16. Genenta Science has a fifty-two week low of $0.55 and a fifty-two week high of $10.00. The company’s 50 day moving average price is $1.45 and its two-hundred day moving average price is $1.12.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered Genenta Science from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Hedge Funds Weigh In On Genenta Science

Large investors have recently bought and sold shares of the stock. SmartHarvest Portfolios LLC purchased a new stake in Genenta Science in the fourth quarter worth $26,000. Citadel Advisors LLC bought a new position in Genenta Science in the 3rd quarter worth approximately $41,000. Alyeska Investment Group L.P. bought a new position in Genenta Science in the 4th quarter worth approximately $328,000. Norges Bank purchased a new position in Genenta Science in the 4th quarter valued at approximately $337,000. Finally, Weiss Asset Management LP purchased a new position in Genenta Science in the 4th quarter valued at approximately $480,000. 15.13% of the stock is currently owned by institutional investors.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.